Why the study?
LVAD patients require lifelong anticoagulation to prevent pump thrombosis, but this combined with acquired coagulopathies carries high bleeding risks, highlighting the need to identify the optimal antithrombotic regimen.
There is a critical need for randomized controlled trials to optimize antithrombotic regimens and manage acquired von Willebrand syndrome in LVAD patients.
LVAD patients require life-long anticoagulant therapy to reduce the risk of pump thrombosis. However, exposing LVAD patients to anticoagulant therapy, in combination with common acquired coagulopathies after LVAD implantation such as acquired von Willebrand syndrome, comes with high risks of bleeding. There is a need for randomized controlled trials in LVAD patients to determine the optimal antithrombotic regimen and find the most effective balance between thrombotic and bleeding complications. In addition, strategies to specifically target the acquired von Willebrand syndrome and its associated angiodysplasias need to be evaluated in the LVAD population.
No takes yet. Share an insight, caveat, or question.
Exter et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: